Literature DB >> 191527

Stimulation of human peripheral blood lymphocytes by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin: differential effects of adherent cells.

A Novogrodsky, K H Stenzel, A L Rubin.   

Abstract

Blastogenic responses of normal human peripheral lymphocytes to three distinct groups of mitogens were studied: Group I--phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM); Group II--soybean agglutinin (SBA) and peanut agglutinin (PNA); and Group III--galactose oxidase (GO) and sodium periodate (IO4-). SBA was mitogenic for human cells, and this effect was enhanced by treating the cells with neuraminidase (NA). PNA was mitogenic only after cells had been treated with NA. GO was effective before and activity was increased after lymphocytes were treated with NA. Responses to Group II and III mitogens were more variable than were those to Group I mitogens. Studies with purified T and B cells indicated that SBA and PNA were T cell mitogens, whereas IO4- and GO failed to stimulate either T or B cells. Adding macrophages back to this system indicated that they were both T cell mitogens with strict macrophage requirements. T cell responses to SBA and PNA were enhanced over responses to unfractionated cells to a degree that could not be explained simply by enrichment of the cultures with T cells. Removal of adherent cells from unfractionated cell suspensions again revealed a marked enhancement of responses to SBA and PNA, a consistent decrease in responses to IO4-, and a variable decrease in responses to GO. Similar results were found with 14C-leucine and 3H-uridine incorporation, as well as 3H-thymidine for the assessment of bastogenic response. Mechanisms responsible for these differential effects of macrophage depletion on lymphocyte responses to different groups of mitogens are yet to be determined. Either different mitogens require different lymphocyte to macrophage ratios for optimal stimulation, or some mitogens (i.e., SBA and PNA) form inhibitory complexees in the lymphocyte-macrophage mixture. In any case, variability in response to mitogenic agents in normal as well as pathologic states may be dependent on adherent cell populations, rather than on the lymphocytes themselves.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191527

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The effect of human monocytes and macrophages on lymphocyte proliferation.

Authors:  J H Passwell; M Levanon; J Davidsohn; F Kohen; B Ramot
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

2.  Mitogen-activated Xenopus laevis lymphocytes produce a T-cell growth factor.

Authors:  D Watkins; N Cohen
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

3.  Effects of ozone on some biological activities of cells in vitro.

Authors:  V Cardile; X Jiang; A Russo; F Casella; M Renis; M Bindoni
Journal:  Cell Biol Toxicol       Date:  1995-02       Impact factor: 6.691

4.  Inhibition of pokeweed mitogen-induced B cell differentiation by compounds containing primary amine or hydrazine groups.

Authors:  G de Boccardo; D Drayer; A L Rubin; A Novogrodsky; M M Reidenberg; K H Stenzel
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

5.  Influence of route of Mycobacterium lepraemurium injection on susceptibility to mouse leprosy and on lymphoblastic transformation.

Authors:  R Turcotte
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  The cysteine-rich regions of the regulatory domains of Raf and protein kinase C as retinoid receptors.

Authors:  B Hoyos; A Imam; R Chua; C Swenson; G X Tong; E Levi; N Noy; U Hämmerling
Journal:  J Exp Med       Date:  2000-09-18       Impact factor: 14.307

7.  Generation of a lymphocyte growth factor by treatment of human cells with neuraminidase and galactose oxidase.

Authors:  A Novogrodsky; M Suthanthiran; B Saltz; D Newman; A L Rubin; K H Stenzel
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.